Immatics Biotechnologies GmbH has appointed Rainer Kramer as chief business officer. In this newly created role, Dr. Kramer will lead its business development unit in order to create optimal value from the company's pipeline of therapeutic cancer vaccines. Dr. Kramer has many years of business development experience within the pharmaceutical industry. He joins from Signature Diagnostics, an oncology diagnostics company where he was chief business officer.